# Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-ai-27-019-impact-of-initial-influenza-exposure-on-immunity-in/  
Official notice: https://www.grants.gov/search-results-detail/359939

> National Institutes of Health offered grants of up to $3.0 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 3 awards worth $9.6 million in total. Applications closed on June 4, 2026.

| Field | Value |
|---|---|
| Opportunity number | RFA-AI-27-019 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | June 4, 2026 |
| Award ceiling | $3.0 million |
| Award floor | not stated |
| Expected awards | 3 |
| Total funding | $9.6 million |
| Cost sharing | not required |
| Assistance Listings | 93.855 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. This new requirement was effective, May 1, 2025.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

## What the grant funds

The purpose of this notice of funding opportunity (NOFO) is to support the establishment or continuation of longitudinal infant cohorts to determine and compare how initial and repeated natural influenza infections and/or influenza vaccinations shape infant and childhood immunity to future influenza exposures. The goal of this research is to understand how these exposures influence immune responses to subsequent influenza infections and/or vaccines and provide key information to facilitate design of durable, broadly protective influenza vaccines.

## Questions people ask

### Is RFA-AI-27-019 still open?

No. It closed on June 4, 2026.

### Who can apply for Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial Not Allowed)?

Closed June 4, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $3.0 million each. About $9.6 million in total across about 3 awards.

### Who has won Allergy and Infectious Diseases Research grants before?

The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.